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Background: This study was carried out to determine the potential of neuronal specific enolase (NSE) as a stage
diagnostic marker in human African trypanosomiasis.
Methods: Plasma and cerebrospinal fluid were obtained from a cohort of Trypanosoma brucei rhodesiense-
infected patients and non-infected controls. Neuronal specific enolase concentrations were measured by
ELISA and analysed in relation to diagnosis and disease-stage data.
Results: Plasma NSE concentration was significantly increased in late-stage patients (median 21 ng/ml), com-
pared to the control (median 11 ng/ml), but not in early-stage patients (median 5.3 ng/ml). Cerebrospinal fluid
NSE concentration did not vary between stages.
Conclusion: Plasma NSE is a potential stage diagnostic in this cohort and merits further investigation.
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Introduction
Human African trypanosomiasis (HAT) is caused by African trypa-
nosomes of the sub-species Trypanosoma brucei rhodesiense and
Trypanosoma brucei gambiense. In both sub-species, infections
progress through two stages, the early or haemolymphatic
stage and the late or meningoencephalitic stage where parasites
invade the central nervous system (CNS).1 In both clinical cases
and experimental models the late stage of disease is associated
with neuro-inflammatory pathology, including astrogliosis and
neuronal degeneration.2–4 The detection of CNS invasion by trypa-
nosomes is of enormous clinical diagnostic importance, as
chemotherapy for late-stage HAT carries increased toxicity risks
than that for early-stage. In T.b. rhodesiense infections, late-
stage disease is treated with the arsenical melarsoprol, which
has a drug-induced fatality rate that may be as high as 5%.5 In
T.b. gambiense infection, the introduction of the nifurtimox-
eflornothine combination treatment has reduced toxic side-
effects, but there remains a significant logistic challenge to
making this treatment available on a large scale.6 Therefore,
prompt and correct staging of diagnosed HAT cases is of vital
clinical importance.
Currently, staging depends entirely on the analysis of cerebro-
spinal fluid (CSF), and all patients with a positive HAT diagnosis
undergo lumbar puncture. The current late-stage diagnostic cri-
teria are the presence of trypanosomes in the CSF or a CSF
leucocytosis of greater than 5 cells/ml.7 Various other CSFmarkers
of neuroinflammation have also been shown to have stage diag-
nostic potential, either singly6 or in multi-analyte panel assays.8
However, these methods all continue to rely on the invasive pro-
cedure of lumbar puncture to obtain CSF. Given that the initial
diagnosis of HAT is made using a blood sample, it would ideal to
also obtain disease-stage data from serum or plasma.9
In this study, the CSF and plasma concentrations of the
enzyme neuronal specific enolase (NSE) were studied retrospect-
ively in patients infected with T.b. rhodesiense. Neuronal specific
enolase is an isoenzyme (gg isoform) of enolase that is found in
high concentrations in neurons and neuroendocrine cells, and is a
sensitive marker for neuronal damage.10 It is able to diffuse rap-
idly across the blood-brain barrier,11 and would therefore be
expected to be a sensitive plasma marker for CNS trauma.
Plasma NSE has also been shown to be a useful marker for neur-
onal injury both in clinical cases11 and in experimental models.13
There have been no previous studies of this marker in HAT
infections.
Methods
The 143 plasma and CSF samples used in this studywere obtained
from the LIRI Clinic, Tororo and Serere Health Centre in eastern
Uganda. These samples were from a larger epidemiological
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study and recruitment and the associated clinical and patho-
physiological data collection have been described elsewhere.14
Thirty-seven control plasma sampleswere obtained from patients
at the clinic who were suspected of having HAT, but later diag-
nosed as non-infected. Diagnosis of HAT was made by micro-
scopic detection of trypanosomes. Stage was determined using
the WHO criteria in which patients with trypanosomes in the
CSF and/or a cell count of .5 cells/mm3 were classified as late-
stage.15 Early-stage infection was treated with suramin and late-
stage infection with melarsoprol (as described in MacLean
et al.16), with post-treatment samples obtained at 36–42 days
post-admission. Individual written informed consent was
obtained from all study participants. Individuals with malarial
parasitaemia and microfilaraemia were excluded from the study.
Blood samples obtained before treatment commenced were
collected into K-EDTA Vacutainers (Vacuette, Greiner, Stroud, UK)
and centrifuged for 10 min at 3000 g. Platelet-depleted plasma
were aliquoted and frozen within 1 h of collection in liquid nitro-
gen. Cerebrospinal fluid samples, obtained as part of normal stage
diagnosis, were also frozen and stored in liquid nitrogen. All sam-
ples were kept in liquid nitrogen for the duration of the field study
(6–18 months), after which they were shipped to the UK, thawed
once, aliquoted and stored at 2808C until analysis.
Neuronal specific enolase concentrations were analysed using
a sandwich ELISA specific for the g subunit (Kit 0050, Alpha
Diagnostics, San Antonio, TX, USA) according to themanufacturer’s
instructions. Samples were analysed in triplicate aliquots of 25 ml.
Concentrations of NSE below the detection limit of the assay were
scored as 0.5 x limit of detection for analysis.17 Haemoglobin con-
centrations in plasma samples were measured in triplicate using
the alkaline hematin detergent method.18 Data analysis was car-
ried out using JMP10.0 (SAS Institute Inc., Cary, NC, USA).
Results and Discussion
The study analysed plasma and CSF from 143 T.b. rhodesiense
HAT-patients and 37 non-infected controls. Of the 143 HAT
patients, 109 cases were diagnosed as late-stage and 34 as early-
stage. The demographic details of the patient group are provided
in the Supplementary data. There were no recorded relapses over
a one-year follow-up period, indicating the accuracy of the early-
stage diagnosis.
Patients in the late-stage showed significantly elevated levels of
plasma NSE (median 21 ng/ml) compared to patients in the early-
stage (median 5.3 ng/ml; p,0.001; Mann-Whitney test) and
control individuals (median 11.0 ng/ml; p,0.01) (Figure 1A). No
relationship was detected between plasma NSE concentration
and patient age or gender (standard least squares model),
nor was any relationship detected with recorded thick-film parasit-
aemia data (Spearmann r20.07). Control plasma NSE concentra-
tions were consistent with previous reports.12,19 The increased
concentration levels of plasma NSE in late-stage cases was similar
to levels detected in patients with traumatic brain injury10 or acute
ischaemic stroke.12 As haemolytic plasma may contain red blood
cell ga isoforms of enolase,20 plasma haemoglobin concentrations
were determined. Haemoglobin levels in the study samples were
low (median 6 mg/dl; IQR 5–9 mg/dl) and showed no relationship
with the detected NSE concentrations (Spearmann r 20.12).
Neuronal specific enolase concentrations were also measured in
plasma prepared from patient blood samples at the time of dis-
charge from treatment (36–42 days post-admission). In these sam-
ples, there was no longer any significant difference between
early-stage (median 6.1 ng/ml) and late-stage (median 8.2 ng/ml)
NSE concentrations, which were also not significantly different to
control concentrations (11 ng/ml). When plasma NSE concentra-
tions of individual patients were compared, for early-stage patients
there were no significant change in plasma NSE concentration after
treatment, whereas there was a significant reduction in NSE con-
centration in the late-stage patients (Wilcoxon Signed Rank
test; p,0.001).
Plasma NSE was predictive of disease stage (OR per unit
increase in NSE was 1.04 [95% CI 1.02–1.08; p,0.0001]), but
the large number of outliers in both stages resulted in limited
diagnostic potential. The area under the receiver operator curve
Figure 1. Neuronal specific enolase (NSE) concentrations in Trypanosoma brucei rhodesiense HAT patients on admission and after a chemotherapeutic
treatment (AT). (A) Plasma NSE concentration in control (n¼37), early (n¼34) and late-stage (n¼109) are shown. Boxes are median and IQR, whiskers
10th and 90th percentiles and dots represent outliers. * indicates a significant increase over the control (p,0.01). (B) Receiver operating characteristic
(ROC) plot of sensitivity and specificity of plasma NSE concentration as a diagnostic for late-stage HAT.
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(ROC) was 0.73 (Figure 1B), and at the optimal diagnostic cut-off
value for late-stage of 10.4 ng/ml, NSE sensitivity was 75% and
specificity was 72%. While this is not adequately discriminating
to be used in a clinical diagnosis, it does represent the first dem-
onstration of a late-stage specific marker in blood.
While the plasma NSE concentrations showed a stage-specific
increase in HAT patients, in the CSF samples no effect was
observed. Cerebrospinal fluid concentrations of NSE were mostly
low (early-stage 1.2 ng/ml [IQR 1.2–1.2 ng/ml] and late-stage
1.2 ng/ml [IQR 1.2–7.6 ng/ml]) and consistent with previously
reported control values.21,22 Interestingly, high levels NSE have
been reported after traumatic brain injury (.100 ng/ml) in ven-
tricular CSF, but no data is available for lumbar CSF. In neurological
diseases, NSE concentrations in lumbar CSF are often low
(,10 ng/ml).23 Given the low levels of NSE detected in the CSF,
it is possible that the source of NSE in the plasma samples was
outside the CNS. Although peripheral neuronal degeneration has
not been investigated in HAT, there is good evidence for CNS neur-
onal degeneration in experimental trypanosomiasis.24 This
requires further investigation in experimental models of infection.
Conclusion
In T.b. rhodesiense HATpatients, plasma NSE levels are significantly
increased compared to the control in late-stage, but not early-
stage patients. As such plasma NSE represents a potential stage
diagnostic, particularly if complementarymarkers can be identified
to increase its diagnostic power. Furthermore, the normalisation of
plasma NSE after treatment of late-stage cases merits further
investigation as a potential treatment efficacymarker. Model infec-
tion studies are now required to identify the source of NSE and
pathophysiological mechanisms underlying its release.
Supplementary data
Supplementary data are available at Transactions Online
(http://trstmh.oxfordjournals.org/).
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